tbuckley/cabot-search huggingface dataset:
Role of Kupffer cells and the spleen in modulation of endotoxin-induced liver injury after partial hepatectomy
Authors: S Suzuki, S Nakamura, A Serizawa, T Sakaguchi, H Konno, H Muro, I Kosugi, S Baba
Journal: Hepatology (1996)

The hypothesis that both activated Kupffer cells and the spleen may be responsible for endotoxin–induced liver injury following partial hepatectomy was investigated. Male rats were divided into a sham group receiving laparotomy alone and three groups receiving a two–thirds hepatectomy; one group was given normal saline (NS) solution as a vehicle control, one group received intravenous gadolinium chloride (GC group) (7 mg/kg body weight) for 2 days before intravenous injection of endotoxin to inhibit Kupffer cell phagocytosis, and the third group simultaneously underwent splenectomy and partial hepatectomy (SH group). As endotoxin, lipopolysaccharide (LPS) (1 mg/kg body weight) was administered intravenously 2 days after surgery. In the GC and SH groups, phagocytic activity was reduced to approximately 40% of that in the sham group. The highest plasma tumor necrosis factor alpha (TNF–alpha) level (8,544 ± 1,223 pg/mL) was observed in the NS group at 1 hour after LPS administration, and the level was significantly reduced by GdCl3 or splenectomy ( P &lt; 0.05). Inhibition of Kupffer cell function and splenectomy attenuated functional and structural liver damage associated with the decreased hepatic infiltration of polymorphonuclear leukocytes (PMNs) and reduced priming of circulating PMNs in the early stage of endotoxemia following partial hepatectomy. Consequently, the 24–hour survival rate of the SH and GC groups was significantly improved to 50% and 80%, respectively ( P &lt; .05), while that of the NS group was 12.5%. These findings indicate that the modification of inflammatory mediator generation by splenectomy or inhibition of Kupffer cell function may be beneficial for the prevention of endotoxin–induced liver injury after partial hepatectomy.
THE CONSTITUTION OF THYROXIN
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Perinatology, Genetics
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ultrasonographic determination of ascitic volume
Authors: J Inadomi
Journal: Hepatology (1996)

The purpose of this study was to develop a method by which ascitic volume can be calculated using transcorporeal ultrasonography, and to determine the accuracy of this method by comparison with the volume of distribution of a radiolabeled tracer (indicator dilution technique [IDT]). Subjects with ascites confirmed by ultrasonography were recruited from the San Francisco General Hospital Gastroenterology and Liver Clinics. With subjects in the prone position on their hands and knees, ultrasonographic measurements were obtained along the ventral surface of the abdomen. The greatest vertical depth of ascitic fluid was recorded, and the abdominal circumference was measured from this point. The ascitic fluid volume was modeled as a segment of a sphere. IDT was performed as the reference method by injecting 99mTc-labeled macroalbumin into the peritoneal cavity and determining the volume of distribution of the indicator. Nine patients were evaluated. The median volume of ascites measured by the IDT was 11.2 L (range, 1.5-17.0 L). The median volume calculated by the ultrasonographic method was 10.3 L (range, 1.2-18.0 L). The correlation coefficient between the ultrasonographic and IDT was 0.96 (P < .001). Our technique accurately determines the volume of ascites using simple ultrasonographic measurements.
OVER-THE-SCOPE-CLIP (OTSC) CLOSURE OF AN IATROGENIC GASTRO-COLIC FISTULA FOLLOWING MAL-DEPLOYMENT OF A LUMEN-APPOSING METAL STENT
Authors: EJ Despott, N Lazaridis, G Johnson, A Podesta, F Solonos, E Athanasiadou, A Skamnelos, R Raymond, N Koukias, T Yano, A Murino
Journal: Endoscopy (2020)

A 44-year-old man with necrotising pancreatitis was referred for EUS-guided drainage of infected 12 × 5 cm symptomatic walled-off-necrosis(WON). At EUS, 20 mm lumen-apposing-metal-stent(LAMS) was deployed through the posterior gastric wall. CT revealed that the LAMS had been inadvertently mal-deployed into the colon.
Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.
Authors: Shukui Qin, Tae Won Kim, Thomas Cheung Yau, Brigette Ma, Hongming Pan, Jian-Ming Xu, Yuxian Bai, Liwei Wang, Kun-Huei Yeh, Feng Bi, Ying Cheng, Tuan Anh Le, Jen-Kou Lin, Tianshu Liu, Ma Dong, Christian Kappeler, Jane Chang, Rui-hua Xu, Jin Li
Journal: Journal of Clinical Oncology (2015)

697 Background: The CONCUR trial (NCT01584830) showed that the multikinase inhibitor regorafenib (REG) significantly improved overall survival and progression-free survival vsplacebo (PBO) in Asian patients with mCRC who had progressed on approved standard therapies. HRQoL was an exploratory endpoint. Methods: In this international multicenter trial conducted in Asia, patients were randomized 2:1 to receive REG 160 mg (n=136) or PBO (n=68) once daily for the first 3 weeks of each 4-week cycle. Prespecified QoL analyses were conducted on all 204 patients using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EuroQol-five dimension questionnaire (EQ-5D). HRQoL outcomes were expressed as time-adjusted area under the curve (AUC) to allow descriptive evaluations of QoL in the REG and PBO groups across the entire treatment period. Individual domains were also compared using descriptive statistics. Results: Overall, changes in HRQoL were similar in the REG and PBO groups. Difference in least-squares (LS) mean time-adjusted AUC of the EORTC QLQ-C30 global health status/QoL (GH) score: −0.40 (95% CI: −3.53 to 2.72); differences in LS mean time-adjusted AUC for EQ-5D index and visual analog scale (VAS) scores: −0.03 (95% CI: −0.08 to 0.01) and −1.18 (95% CI: −4.01 to 1.66), respectively. The PBO group had &lt;5 patients after cycle 3, so results should be interpreted with caution. Changes from baseline scores in cycles 2 and 3 did not appear to differ between REG and PBO on the 15 domains of the EORTC QLQ-C30, the EQ-5D index, and the VAS. Conclusions: No substantial differences in overall changes in HRQoL were seen between patients treated with REG and PBO in the CONCUR trial. Clinical trial information: NCT01584830. [Table: see text]
International study finds breast milk free of significant lead contamination.
Authors: T Sinks, R J Jackson
Journal: Environmental Health Perspectives (1999)

International Study Finds Breast Milk Free of Significant Lead ContaminationThe recent article by Gulson et al. (1) should provide reassurance to most women that their breast milk is free of significant lead contami- nation.Their data found that breast milk con- tained lower levels of lead than infant formula or infant food.Although small amounts of lead may be found in all human tissues, the milk of the vast majority of women does not present a lead hazard to their babies.Unfortunately, the authors formed unwarranted conclusions from their data, and the title of the press release, "International Study Finds Mothers' Lifetime Lead Exposures May Put Breast-fed Newborns at Risk," (2) was misleading.As a result, women reading this press release may decide not to breast-feed, thus depriving their babies of the most healthful food available to them and placing their infants at increased risk for a
NEUROPSYCHOLOGY
Authors: T. Brinkman, W. Liu, G. Armstrong, A. Gajjar, T. Merchant, C. Kimberg, L. Kun, D. K. Srivastava, J. Gurney, L. Robison, M. Hudson, K. Krull, J. Rubens, R. R. Lulla, J.-S. Lai, J. Fangusaro, K. Wolfe, A. Madan-Swain, A. Reddy, G. Hunter, J. Banos, R. Kana, A. Resch, K. von Hoff, A. O. von Buren, C. Friedrich, W. Treulieb, C. Lindow, R. Kwiecien, H. Ottensmeier, S. Rutkowski, C. L. Armstrong, P. C. Phillips, R. A. Lustig, C. Stamos, Y. Li, J. Belasco, J. E. Minturn, M. J. Fisher, T. Heinks-Maldonado, K. Wingeier, V. Lory, C. Schafer, M. Studer, M. Steinlin, K. Leibundgut, M. de Ruiter, N. Schouten, J. Greidanus, M. Grootenhuis, J. Oosterlaan, A. L.-V. A, J. Grill, S. Puget, C. Sainte-Rose, C. Dufour, V. Kieffer, G. Dellatolas, E. B. -Shkedi, M. W. Ben Arush, H. Kaplinsky, S. Ash, Y. Goshen, I. Yaniv, I. J. Cohen, J. M. Levy, T. Tello, X. Lu, D. Gao, G. Wilkening, A. Donson, N. Foreman, A. Liu, J. Korzeniewska, B. D. Baginska, D. Perek, S. Staccioli, D. Chieffo, M. Petrarca, I. Moxon-Emre, M. Taylor, E. Bouffet, D. Malkin, C. Hawkins, N. Scantlebury, D. Mabbott, T. Cunningham, E. Bouffet, N. Scantlebury, J. Piscione, D. Igoe, M. Orfus, U. Bartels, S. Laughlin, U. Tabori, D. Mabbott, K. Hardy, B. Carlson-Green, H. Conklin, C. Dockstader, E. Bouffet, F. Wang, D. Mabbott, S. Bostan, C. Dockstader, N. Scantlebury, E. Bouffet, F. Liu, F. Wang, D. Mabbott, P. Zou, Y. Li, H. M. Conklin, R. K. Mulhern, R. W. Butler, R. J. Ogg, T. Diver, P. Manley, M. Kieran, C. Chordas, C. Liptak, B. Delaney, S. Brand, C. Rey-Casserly
Journal: Neuro-Oncology (2012)
MEDICAL SUBJECTS ON THE STAGE.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Update: photoradiation therapy for cancer
Authors: T. Hager
Journal: JAMA (1982)

Complete remissions of early stage human lung and bladder cancers have been obtained with an experimental form of therapy called photoradiation therapy (PRT). Researchers presenting the studies at the XIII International Cancer Conference in Seattle were enthusiastic about the treatment, entailing use of a photosensitizing agent activated by exposure to visible light. A dozen hospitals in the United States are already using this technique, and as many more are gearing up to do so. But some investigators caution that results are still preliminary and that the treatment seems applicable only to a limited number of patients. The key to the therapy is hematoporphyrin derivative (HpD), which "seems to have most of the qualities we want in a photosensitizing agent to treat cancer," according to Thomas J. Dougherty, PhD, of Roswell Park Memorial Institute in Buffalo, who has pioneered the development of the HpD system (<i>JAMA</i>[MEDICAL NEWS] 1979;242:403). Three days
ANGI-04. HIGH RESOLUTION RNAseq PROFILING OF GLIOBLASTOMA RESIDUAL INVASIVE CELLS ISOLATED BY A NOVEL 5ALA FLUORESCENCE BASED METHOD
Authors: Jonathan Rowlinson, Maria Estevez-Cebrero, Anbarasu Lourdusamy, Ruman Rahman, Stuart Smith
Journal: Neuro-Oncology (2017)

Glioblastoma (GBM) is a polyclonal tumor with molecular abnormalities varying temporo-spatially (intra-tumor heterogeneity), one mechanism of therapy resistance. Fluorescence guided neurosurgical resection is performed with prior administration of 5-aminolevulinic acid (5-ALA) leading to individually fluorescent tumor cells mixed within a background population of non-neoplastic cells in the invasive region beyond “pure” tumor. We have isolated this critical invasive population by 5ALA-based fluorescence activated cell sorting (FACS) to study invasive GBM without an overwhelming background “normal” signal. We performed high-resolution RNAseq analysis on 45 specimens from 10 GBM patients including samples from tumor core, rim, invasive zone and GBM cells from within brain parenchyma by 5-ALA based FACS. Genome-wide gene expression analysis (Affymetrix) on 14 glioma samples from three different GBM patients was also undertaken, with validation by qPCR and immunohistochemistry. Fluorescent cancer cells accounted for an average of 1% of the samples subjected to FACS. High-resolution RNAseq profiles were generated for tumor regions and fluorescently isolated invasive cells. Statistical analysis by linear models identified 325 differentially expressed genes between FACS positive cells and other tumor regions (multiple test adjusted P-value < 0.05), of these, 50 genes were upregulated in all comparisons. These transcriptomic changes orchestrate MAPK (DUSP1, DUSP2, DUSP10 and FOSB), chemokine signaling pathways (CXCL2, CXCL3, CCL20 and NFKB1) and negative regulation of cell proliferation (EREG and KLF6). In contrast, 29 downregulated genes in FACS positive cells were enriched with signal transduction (DDR2 and MTSS1L) and ECM-receptor interaction (COL4A1, COL4A2, and HSPG2). Residual GBM cells in the invasive zone are shown to exhibit activation of distinct molecular pathways and biological processes. These unique molecular features offer hope for developing more efficacious targeted therapies focusing on this population rather than the bulk tumor that has been the subject of most historical analyses.
PTU-029 Managing the long-term care of inflammatory bowel disease patients: the cost to European health care providers
Authors: J Buchanan, S Wordsworth, J Taylor, D Jewell
Journal: Gut (2010)

<h3>Introduction</h3> Inflammatory Bowel Disease (IBD), which includes Crohn9s disease (CD) and Ulcerative Colitis (UC), is a chronic condition characterised by substantial morbidity. Patients with IBD are considered expensive to manage although their use of health care resources has not been sufficiently estimated. To date, few studies have quantified the total cost of caring for IBD patients, preferring to focus on the cost-effectiveness of specific treatments instead. Estimating the resources used and costs incurred when caring for IBD patients is crucial to help healthcare providers plan patient clinical management. This need intensifies with advances in biological therapies and genetic diagnostic tools such as microarrays. Our study developed a framework to estimate the total cost of caring for IBD patients. This framework allows both the estimation of the costs of current care pathways in various settings, and the economic analysis of proposed future interventions. We apply the framework to consider the cost of care for UC and CD patients in the UK and mainland Europe. <h3>Methods</h3> Decision models were built to simulate the natural disease history of UC and CD based on clinical pathways mapped in four European hospitals. A healthcare provider perspective was adopted and model inputs applied from published sources and expert opinion. Two hypothetical cohorts of 10 000 UC/CD patients presenting with symptoms of varying severity were modelled over a 10-year period. The average starting age ranged from 25 to 85 years and the models were adjusted to capture differences in clinical management across Europe. Healthcare cost data (test, treatment, surgery, consultation costs) were taken from UK sources and expressed in 2008 prices. <h3>Results</h3> The average cost of care over the entire 10-year period for a 45-year-old UC/CD patient was £8035/£7759 in the UK and £7657/£9546 in mainland Europe. These costs are comparable with previous estimates. The average cost per patient fell with patient age. Much of the clinical course for both patient groups was spent in remission, and most costs were incurred soon after diagnosis. The costs of surgery, azathioprine and hospital admission had the greatest effect on the results. <h3>Conclusion</h3> Our study confirms that IBD patients are expensive to manage and illustrates the importance of differentiating between alternative clinical management scenarios. The framework we develop is an informative analytical tool which allows healthcare providers to predict the resources required and costs incurred from treating both current and future IBD patients. We acknowledge EC financial support and assistance received from members of the IBDchip consortium.
Commentaire de travail de A. D. Hopper et al., pp. 219
Journal: Endoscopy (2008)

See also: Patchy villous atrophy in adult patients with suspected gluten-sensitive enteropathy: is a multiple duodenal biopsy strategy appropriate?Endoscopy 2008; 40(03): 219-224DOI: 10.1055/s-2007-995361
Correction
Journal: BMJ (1961)

should be regulated by the results.It should be maintained for several months after improvement and only gradually reduced.Attention should also be paid to diet and to ensuring an ample fluid intake.Rash After Alcohol Q.-A healthy woman aged 35 has complained for the past four years of a blotchy, burning ervthematous rash on both sides of the neck and.when severe, in the inter- clavicular area about 20 minutes after taking even minimal amounts of alcohol in any form.Rarely the rash may also be caused by emotional distress.Can anything be done to prevent this?A.-This may be purely an emotional reaction in which one of the trigger mechanisms to set it off may be alcohol.Such peculiar personal reactions are known to occur.However, a careful clinical overhaul and certain investiga- tions may be indicated to exclude such disorders as Hodgkin's disease.carcinoid, phaeochromocytoma, and cholinergic reactions.All these upon occasion can be reactive to alcohol, giving itching or erythema and urticaria or pain.It may be necessary to consider the problem in that context.though it is not suggested by the little information given.Treatment generally calls for avoidance of the cause.
Health and Environment.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ANOTHER PORTER NARCOTIC BILL
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal